Hormone replacement therapy is not a single treatment. It is a clinical approach that looks fundamentally different depending on which hormones are declining, why they are declining, what symptoms they are producing, and what health risks need to be weighed against the benefits. The differences between HRT for men and HRT for women run deeper than simply “different hormones” — they extend to the hormonal systems being addressed, the timing of intervention, the delivery methods used, the monitoring required, and the long-term health implications of both treating and not treating hormonal decline. What men and women share is the underlying principle: when hormone levels fall below the range needed for optimal function, the body’s systems begin to deteriorate in predictable, measurable ways. Replacing those hormones — carefully, at appropriate doses, with proper monitoring — can restore function and reduce long-term health risk. How that plays out in practice is where the approaches diverge significantly.

What You Need to Know

For women, hormone replacement therapy primarily addresses the consequences of ovarian hormone decline: the loss of estrogen and progesterone that accelerates through perimenopause and reaches its endpoint at menopause. This is an event-driven transition with a relatively defined timeline, and the research on when to intervene, which hormones to use, and what the long-term risks and benefits look like is extensive. For men, hormone replacement therapy addresses the gradual age-related decline of testosterone — a slower, more variable process that does not have a defined endpoint equivalent to menopause. The diagnosis requires both laboratory confirmation of low testosterone and the presence of clinical symptoms, and the evidence base, while substantial, is more fragmented than the menopause literature. In both cases, the goal is the same: restore hormonal sufficiency to relieve symptoms, protect long-term health, and preserve quality of life. The path to get there differs considerably.

The Hormones Involved: A Fundamental Difference

The most basic difference between male and female HRT is which hormones are being replaced and why.

For Women:

The primary hormonal losses driving menopausal symptoms are estrogen (specifically estradiol, the most biologically active form of estrogen during reproductive years) and progesterone. These hormones decline as the ovaries stop cycling, producing a wide range of symptoms from hot flashes and sleep disruption to bone loss, cardiovascular changes, and cognitive effects. Women with an intact uterus require both estrogen and progesterone when receiving systemic hormone therapy. Estrogen alone stimulates the uterine lining, and without progesterone to oppose this effect, the risk of endometrial hyperplasia and uterine cancer rises significantly. Women who have had a hysterectomy can receive estrogen alone without this concern. Testosterone is also an important hormone for women and declines with age, though it does not drive the acute menopausal transition. Low-dose testosterone therapy in women is used to support libido, energy, body composition, and bone density — but it is prescribed at a fraction of the male dose, and no FDA-approved testosterone product exists specifically for women. This is a meaningful gap in the clinical toolkit. DHEA, a precursor hormone, and thyroid hormones are also commonly evaluated and addressed as part of a comprehensive women’s hormone protocol, though they are not exclusive to female HRT.

For Men:

The primary hormonal decline in men is testosterone. Unlike the ovarian shutdown that drives female menopause, male testosterone decline is gradual — roughly 1 to 2 percent per year beginning around age 30 — and varies significantly between individuals depending on genetics, body composition, sleep, stress, metabolic health, and overall lifestyle. There is no male equivalent of the sharp hormonal cliff women experience at menopause. When testosterone is replaced in men, the downstream hormonal effects must also be managed. Testosterone converts to estradiol through aromatization, and in some men — particularly those with higher body fat or a genetic predisposition — this conversion produces elevated estradiol levels that require monitoring and sometimes management. Men also produce small amounts of estrogen naturally, and estradiol plays an important role in bone health, libido, cognitive function, and cardiovascular health in men — the goal is not to eliminate estradiol but to keep it in an optimal range. LH (luteinizing hormone) and FSH (follicle-stimulating hormone) are also affected by testosterone therapy: exogenous testosterone suppresses these pituitary signals, which reduces the testes’ own testosterone production and impairs sperm production. Men who wish to preserve fertility require a modified approach before or during testosterone therapy.

The Clinical Trigger: How Each Transition Is Defined

For Women:

Menopause is defined as 12 consecutive months without a menstrual period, typically occurring between ages 45 and 55. The transition leading to menopause — perimenopause — can begin 4 to 10 years earlier and is often the most symptomatic phase, characterized by erratic hormone levels, irregular cycles, and the emergence of hot flashes, sleep disruption, mood changes, and other symptoms. The clinical trigger for considering HRT in women is typically a combination of symptoms and the stage of the hormonal transition. Lab values alone are not sufficient — FSH and estradiol levels can fluctuate widely during perimenopause and may not reflect how a woman feels on any given day. Symptom severity, quality of life impact, and individual risk factors all factor into the decision. The concept of a “window of opportunity” is central to female HRT: research consistently shows that initiating hormone therapy before age 60 or within 10 years of menopause onset is associated with the most favorable benefit-to-risk ratio for cardiovascular health, bone density, and cognitive function. Starting later does not preclude therapy but changes the risk-benefit calculation.

For Men:

Male hypogonadism — the clinical diagnosis that qualifies a man for testosterone replacement therapy — requires both biochemical confirmation (low testosterone on at least two morning measurements) and the presence of symptoms consistent with testosterone deficiency. Symptoms alone, or lab values alone, are not sufficient for diagnosis according to the major clinical guidelines. There is no equivalent “window” concept for men. The principle of earlier intervention applies — addressing testosterone decline before significant muscle loss, metabolic dysfunction, and cardiovascular changes have accumulated generally produces better outcomes — but the urgency and the defined timing that characterize female menopause management do not have a male parallel. It is also important to distinguish primary hypogonadism (testicular failure) from secondary hypogonadism (pituitary or hypothalamic dysfunction that reduces the signals driving testosterone production). These have different underlying causes and sometimes different treatment approaches. Secondary hypogonadism, in particular, may be addressable by treating the upstream cause rather than simply replacing testosterone.

What Is Prescribed: Hormones, Doses, and Delivery

For Women:

• Estradiol: The primary hormone replaced in menopausal women. Available in FDA-approved transdermal patches, gels, sprays, and oral tablets, as well as vaginal formulations for local genitourinary symptoms. Transdermal delivery is generally preferred over oral for most women because it bypasses first-pass liver metabolism, does not increase clotting risk, and provides more stable blood levels.
• Micronized progesterone: Required for women with an intact uterus taking systemic estrogen. Available as FDA-approved oral micronized progesterone (Prometrium) and as compounded preparations. Taken cyclically or continuously depending on where in the menopausal transition the woman is. Oral micronized progesterone has a mild sedative effect that many women find beneficial for sleep when taken at bedtime.
• Testosterone (low dose): Used in women at doses typically 10 to 20 times lower than male doses. Delivered via compounded cream or gel, as no FDA-approved product exists for women. Supports libido, energy, body composition, bone density, and cognitive function.
• DHEA: Vaginal DHEA (Intrarosa) is FDA-approved for dyspareunia. Systemic DHEA is available through compounding pharmacies and over the counter, though prescription-grade formulations provide more consistent dosing.
• Thyroid hormones: Evaluated and addressed as part of a comprehensive protocol. Women have significantly higher rates of thyroid dysfunction than men, and hypothyroidism is a common contributor to menopausal symptom overlap.

For Men:

• Testosterone: The primary hormone replaced. Available in several FDA-approved delivery methods including injectable testosterone cypionate or enanthate (the most common and cost-effective), transdermal gels and patches, and buccal formulations. Pellets are also used but are compounded and not FDA-approved.
• hCG (human chorionic gonadotropin): Sometimes used alongside testosterone to maintain testicular size and function, or as an alternative to testosterone in men who wish to preserve fertility. hCG mimics LH and directly stimulates the testes to produce testosterone.
• Clomiphene (clomid): A selective estrogen receptor modulator that stimulates the pituitary to produce more LH and FSH, which in turn drives testicular testosterone production. Used as an alternative to exogenous testosterone in men with secondary hypogonadism, particularly those who want to preserve fertility or prefer to stimulate their own production rather than replace externally.
• Anastrozole or other aromatase inhibitors: Sometimes added to a testosterone protocol when aromatization to estradiol is excessive. Not used routinely — estradiol has important functions in men and suppressing it too aggressively causes joint pain, mood changes, reduced libido, and bone loss.
• DHEA: Evaluated and sometimes supplemented, though less prominently in male protocols than female.

Monitoring: What Gets Tracked and Why

Ongoing laboratory monitoring is essential for safe hormone therapy in both sexes, but the specific markers differ significantly.

For Women:

• Estradiol and progesterone levels to confirm therapeutic range
• Testosterone and SHBG if testosterone therapy is included
• Thyroid panel (TSH, free T3, free T4, reverse T3, antibodies)
• Metabolic markers: fasting insulin, glucose, lipid panel
• Bone density (DEXA scan) to track long-term skeletal health
• Breast health monitoring per standard screening guidelines
• Blood pressure monitoring, particularly for women using oral estrogen

For Men:

• Total and free testosterone to confirm therapeutic levels
• Estradiol to monitor aromatization and keep within optimal range
• Hematocrit and hemoglobin — critically important, as testosterone stimulates red blood cell production and elevated hematocrit increases clotting risk
• PSA (prostate-specific antigen) and prostate symptom assessment
• LH and FSH (particularly relevant if fertility preservation is a concern)
• Metabolic markers: fasting insulin, glucose, lipid panel
• Sleep apnea screening, as testosterone can worsen obstructive sleep apnea

Key Risks and Considerations: Where They Differ

For Women:

The most discussed risk in female HRT is breast cancer, and the picture is more nuanced than public perception suggests. The elevated breast cancer risk signal associated with combined hormone therapy in the original Women’s Health Initiative trial was driven primarily by the synthetic progestin medroxyprogesterone acetate (MPA) — not by estradiol or by bioidentical micronized progesterone. Multiple large studies have found that the combination of estradiol and micronized progesterone does not carry the same breast cancer risk elevation as estradiol combined with synthetic progestins. Estrogen alone (in women without a uterus) may modestly reduce breast cancer risk with long-term use. Cardiovascular risk in women is highly route-dependent. Oral estrogen increases clotting protein production and raises VTE (venous thromboembolism) risk. Transdermal estradiol does not carry this risk at standard doses and is the preferred route for women with any cardiovascular or clotting risk factors. The timing hypothesis is the other critical consideration: women who begin hormone therapy within 10 years of menopause or before age 60 appear to derive the greatest cardiovascular benefit and face the most favorable overall risk-benefit ratio. Women who begin therapy more than 10 years after menopause or after age 60 face a different risk profile that requires more individualized assessment.

For Men:

The most clinically significant monitoring concern for men on testosterone therapy is hematocrit elevation (erythrocytosis). When testosterone drives red blood cell production above normal range, blood viscosity increases and the risk of blood clots rises. This requires regular monitoring and, when hematocrit exceeds safe thresholds, dose reduction, delivery method change, or therapeutic phlebotomy. Prostate health is another key consideration. Testosterone does not cause prostate cancer, but it can stimulate pre-existing prostate tissue. Men on testosterone therapy require baseline and ongoing PSA monitoring. Active or recently treated prostate cancer is a contraindication. Cardiovascular effects of testosterone therapy in men have been the subject of significant research and some controversy. Large recent trials, including the TRAVERSE trial published in 2023, found that testosterone therapy in middle-aged and older men with low testosterone and cardiovascular risk factors did not increase the risk of major adverse cardiovascular events compared to placebo. Testosterone therapy appears to have neutral to potentially beneficial cardiovascular effects when administered at appropriate doses to properly selected patients. Fertility impact is unique to men: exogenous testosterone suppresses sperm production and should not be used by men who wish to conceive without a parallel strategy to preserve fertility.

What Men and Women Share: The Common Principles

Despite the significant differences in hormones, timing, monitoring, and risk profiles, men and women benefit from the same foundational principles in hormone therapy:

• Comprehensive evaluation before starting: Symptoms alone are not sufficient to prescribe hormone therapy. A thorough baseline assessment of hormone levels, metabolic health, thyroid function, cardiovascular risk, and relevant health history is essential for both sexes.
• Individualized dosing: There is no standard dose that works for everyone. The goal is to restore physiological levels that relieve symptoms and support health — not to maximize hormone levels.
• Ongoing monitoring: Neither male nor female hormone therapy is “set it and forget it.” Regular lab work, symptom assessment, and dose adjustment are essential components of safe and effective therapy.
• Lifestyle as the foundation: Hormone therapy works best when supported by adequate protein intake, resistance training, quality sleep, and stress management. Hormones restore the biological environment — lifestyle determines what you do with it.
• Addressing root causes alongside hormones: Both male and female hormone protocols are most effective when underlying contributors to hormonal decline — insulin resistance, thyroid dysfunction, nutritional deficiencies, sleep disorders, chronic stress — are identified and addressed concurrently.

Safety

Hormone replacement therapy is a medical treatment with real risks that must be weighed against real benefits for each individual patient. The decision to start therapy — and which therapy, at what dose, delivered how — should be based on a thorough evaluation by a qualified provider who reviews your complete health picture, not on symptoms alone or on a standardized protocol that does not account for individual variation. Seek immediate medical care if you experience chest pain, shortness of breath, sudden severe headache, one-sided weakness or numbness, calf pain or swelling, unexpected vaginal bleeding, or signs of severely elevated hematocrit (men on testosterone). These symptoms require urgent evaluation regardless of timing or current dose.

Sources

• North American Menopause Society (NAMS) — 2022 Hormone Therapy Position Statement
• Lincoff et al. — Cardiovascular Safety of Testosterone-Replacement Therapy: TRAVERSE Trial (NEJM, 2023)
• Endocrine Society — Testosterone Therapy in Men with Hypogonadism (Clinical Practice Guideline, 2018)
• ACOG — Compounded Bioidentical Menopausal Hormone Therapy (Clinical Consensus, 2023)

This content is for educational purposes and does not substitute personalized medical advice.